FDA Approves Pembrolizumab, Lenvatinib Combination Therapy for Advanced Endometrial Carcinoma
July 22nd 2021The FDA has approved pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient
Read More
Engaging Colleges of Pharmacy to Assist Establishing Payer-Provider Relationships
July 22nd 2021During a presentation at the 2021 annual meeting of the American Association of Colleges of Pharmacy, the presenters broke down how best to engage colleges of pharmacy to help in establishing payer-provider relationships.
Read More
Study: Ultra-Processed Food Associated With Higher Risk of Inflammatory Bowel Disease
July 22nd 2021Because white meat, unprocessed red meat, dairy, starch, fruit, vegetables, and legumes were not associated with the development of IBD, the way that the food is processed may confer this risk of IBD, rather than the food itself.
Read More
Expert: The Future of Products Containing Rare Cannabinoids is in Pharmacy
July 22nd 2021Pharmacy Times interviewed Dennis O’Neill, president and board member of BIOMEDICAN, on the outlook around the future of biosynthesis therapeutics that use rare cannabinoids to treat a range of health issues, from mental health disorders to diabetes.
Watch
FDA Grants Breakthrough Therapy Designation to Venetoclax for Higher Risk Myelodysplastic Syndromes
July 22nd 2021Venetoclax is already approved for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in some adults with newly diagnosed acute myeloid leukemia.
Read More
The Reasons Behind Bipartisan Support for Granting Pharmacists Provider Status for Medicare Part B
July 21st 2021Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, outlined what has led to legislation granting pharmacists provider status gaining bipartisan support.
Watch
FDA Advisory Committee Members Raise Concerns About Aducanumab
July 21st 2021In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.
Watch